ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1119

Genetic Signatures from RNA Sequencing of Pediatric Localized Scleroderma (LS) Skin

Emily Mirizio1, Roosha Mandal2, Qi Yan3, William Horne4, Kaila Schollaert-Fitch3 and Kathryn S. Torok5, 1Peds Rheum, University of Pittsburgh Med Ctr, Pittsburgh, PA, 2Carnegie Mellon University, Pittsburgh, PA, 3University of Pittsburgh Med Ctr, Pittsburgh, PA, 4Health Sciences Sequencing Core at Children's Hospital of Pittsburgh, Pittsburgh, PA, 5Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: pediatric rheumatology and scleroderma, RNA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Systemic Sclerosis and Related Disorders – Basic Science Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Localized scleroderma (LS) is a progressive disease of the skin and underlying tissue that causes significant functional disability and disfigurement, especially in developing children. During the active inflammatory stage of the disease, systemic immunosuppressive therapy intervention can halt disease progression and ameliorate disease features such as joint contractures. The existing clinical process for determining when LS is active and susceptible to intervention and when to gradually stop intervention is often convoluted. Commercially available inflammatory serologic markers currently have limited utility in the clinical assessment of active disease. RNA sequencing (RNAseq) technology allows for improved understanding of relevant cellular expression through transcriptome analysis of specific time points during LS disease progression. It also permits the use of RNA extracted from existing paraffin-embedded skin tissue increasing the availability of samples.

Methods:

RNAseq was performed on paraffin-embedded skin (n=15 LS, n=5 pediatric healthy) and RNAlater preserved skin specimens (n=2 LS, n=4 healthy) using the Illumina HTS using TrueSeq Access library preparation and collected through IRB#PRO11060222. Paired end RNA sequencing data was aligned using STAR and analyzed for differential gene expression (DEGs) using DESeq2. Genes were analyzed using DEG cutoffs of log2fold change > ±2.5, adjusted p<0.05, and a false discovery rate (FDR) cutoff of <0.01 for enrichment software (GSEA©). PCA and hierarchical clustering was performed using Cluster 3.0 and Partek® softwares. Clinical subtype data (active/inflammatory vs. stable/disease damage) was applied to these clustering techniques.

Results:

A strong correlation (rS=0.90, p=0.0001) was observed between the comparison of genes expressed between fresh (RNAlater) and paraffinized skin in healthy and LS subjects.  When compared to healthy controls, we observed distinct expression of an inflammatory response gene signature (IRGS) composed of IFNγ, IFNα and TNFα associated genes. GSEA© enrichment analysis showed the IRGS, including interferon inducible chemokines such as CXCL9, CXCL10, CXCL11 and IFNγ itself, was more highly expressed in LS patients with more inflammatory lesions (see Figure).

Conclusion:  

The use of paraffinized skin for sequencing was proven to be an effective substitute for fresh skin by comparing gene expression profiles. The prevalence of the IFNγ signature in the lesion biopsies of active LS patients indicates these genes are reflecting clinical parameters and provide insight into disease propagation, possibly a Type 1 monocyte or T-cell response, which will be further investigated in regard to disease propagation.


Disclosure: E. Mirizio, None; R. Mandal, None; Q. Yan, None; W. Horne, None; K. Schollaert-Fitch, None; K. S. Torok, None.

To cite this abstract in AMA style:

Mirizio E, Mandal R, Yan Q, Horne W, Schollaert-Fitch K, Torok KS. Genetic Signatures from RNA Sequencing of Pediatric Localized Scleroderma (LS) Skin [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/genetic-signatures-from-rna-sequencing-of-pediatric-localized-scleroderma-ls-skin/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genetic-signatures-from-rna-sequencing-of-pediatric-localized-scleroderma-ls-skin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology